Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-13

Clinical Trial Update: Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for NPI-0052 in relapsed/refractory multiple myeloma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NPI-0052 (Salinosporamide A)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-13